Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Financing Activities (2016 - 2026)

Anika Therapeutics has reported Cash from Financing Activities over the past 17 years, most recently at -$10.3 million for Q1 2026.

  • Quarterly Cash from Financing Activities fell 90.27% to -$10.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$15.5 million through Mar 2026, up 2.73% year-over-year, with the annual reading at -$10.6 million for FY2025, 17.11% up from the prior year.
  • Cash from Financing Activities was -$10.3 million for Q1 2026 at Anika Therapeutics, down from -$5.3 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $667000.0 in Q4 2022 and troughed at -$10.3 million in Q1 2026.
  • The 5-year median for Cash from Financing Activities is -$1.6 million (2023), against an average of -$2.6 million.
  • Year-over-year, Cash from Financing Activities soared 1011.67% in 2022 and then plummeted 10645.65% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $667000.0 in 2022, then plummeted by 48.73% to $342000.0 in 2023, then crashed by 1665.5% to -$5.4 million in 2024, then increased by 1.4% to -$5.3 million in 2025, then plummeted by 96.0% to -$10.3 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Cash from Financing Activities are -$10.3 million (Q1 2026), -$5.3 million (Q4 2025), and -$13000.0 (Q3 2025).